Fred Alger Management Inc. lowered its position in Humana Inc. (NYSE:HUM) by 11.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 398,391 shares of the insurance provider’s stock after selling 52,220 shares during the period. Fred Alger Management Inc. owned 0.28% of Humana worth $95,861,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Acrospire Investment Management LLC bought a new stake in shares of Humana in the 2nd quarter valued at $120,000. Independent Portfolio Consultants Inc. increased its position in shares of Humana by 22.1% during the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock worth $125,000 after buying an additional 94 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in Humana by 139.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock worth $134,000 after buying an additional 325 shares during the last quarter. Fiduciary Trust Co. bought a new position in Humana during the second quarter worth $135,000. Finally, Guardian Life Insurance Co. of America raised its stake in Humana by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock worth $119,000 after buying an additional 4 shares during the last quarter. Hedge funds and other institutional investors own 95.12% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/fred-alger-management-inc-has-95-86-million-holdings-in-humana-inc-hum/1605670.html.

HUM has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $262.00 price target for the company in a report on Wednesday, June 7th. BidaskClub lowered Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, June 13th. UBS AG reissued a “neutral” rating and issued a $237.00 price objective (up from $205.00) on shares of Humana in a research note on Wednesday, June 28th. Royal Bank Of Canada reissued a “hold” rating and issued a $214.00 price objective on shares of Humana in a research note on Monday, June 5th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $246.00 target price on shares of Humana in a research report on Friday, July 14th. Nine research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $247.50.

Humana Inc. (HUM) traded up 0.771% on Tuesday, reaching $246.889. 289,869 shares of the company’s stock were exchanged. The company has a market cap of $35.68 billion, a PE ratio of 20.310 and a beta of 0.86. Humana Inc. has a 52-week low of $163.50 and a 52-week high of $259.76. The firm’s 50 day moving average price is $249.26 and its 200 day moving average price is $233.71.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The business had revenue of $13.53 billion for the quarter, compared to analysts’ expectations of $13.61 billion. During the same quarter last year, the company posted $2.30 EPS. On average, analysts expect that Humana Inc. will post $11.55 earnings per share for the current year.

The business also recently disclosed a dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 29th will be paid a $0.40 dividend. The ex-dividend date is Thursday, September 28th. Humana’s dividend payout ratio (DPR) is 13.06%.

In related news, CEO Bruce D. Broussard sold 12,000 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $251.88, for a total value of $3,022,560.00. Following the completion of the sale, the chief executive officer now directly owns 80,086 shares of the company’s stock, valued at approximately $20,172,061.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP M Todoroff Christopher sold 22,935 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $252.52, for a total transaction of $5,791,546.20. Following the completion of the sale, the vice president now directly owns 24,001 shares of the company’s stock, valued at $6,060,732.52. The disclosure for this sale can be found here. Insiders sold a total of 55,595 shares of company stock valued at $14,133,706 over the last 90 days. 0.80% of the stock is currently owned by company insiders.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.